Our Vision

Manbok Kim, PhD

ViroCure Founder

Asst. Professor @ Dankook Univ.

Oncolytic virologist

Naturally occurring viruses are live replication-proficient viruses specifically infecting human cancer cells while sparing their normal counterparts.


Since the discovery of naturally oncotropic viruses in the 1920s, various replicating viruses have shown degrees of safety and efficacy in pre-clinical and clinical application for human anti-cancer therapeutics. Cellular oncogenes such as Ras and c-Myc are known to be important host genes for oncolytic viral tropism decision.


Importantly, we recently discovered that cellular tumor suppressor genes are also important in determining oncolytic viral tropism. Carcinogenesis is a multi-step process involving accumulation of not only oncogene abnormality but also the accumulation of tumor suppressor gene abnormality. Thus, it is interesting that oncolytic viruses are known to exploit abnormal oncogene and cellular tumor suppressor signaling, frequently dysregulated in various human malignancies, for their decision of oncolytic specificity and efficacy.


Unlike oncogenes, many tumor suppressor genes such as p53, ATM, and RB are known to play important roles in genomic fidelity & maintenance. Thus tumor suppressor gene abnormality could affect host genomic integrity and likely disrupt intact antiviral networks due to accumulation of genetic defects resulting in natural viral oncotropism.


ViroCure finds naturally occurring oncotropic viruses for targeting various human or animal malignancies, to develop safe and effective treatments to a wide variety of illnesses.

October 2013

Oncolytic virus research group formed in Dankook University

June 2016

Establishment of ViroCure, Inc.

July 2016

Startup investment from ActnerLab

October 2016

Startup investment from Suprema Investment

November 2016

Startup investment from Wonik Investment Partners

December 2016

R&D Lab established in Seoul Guro-digital Complex. ViroCure approved by Korea Technology Finance Corporation for Venture Inc.

February 2017

ViroCure accepted as an incubating company in Yancheng Rehoboth business center in China

March 2017

ViroCure accepted as a resident company to the Tampa Bay Technology Incubator program in the United States

January 2018

ViroCure facility launched at UMass Lowell's Massachusetts Medical Device Development (M2D2) Center.

Tommy Alain, PhD

Assistant professor @ Ottawa University. CHEO scientist. University of Calgary, McGill University. Oncolytic virologist.

Chung-Soo Kim, MPhD

Professor @ ASAN Medical Center, R&D Director. Seoul Medical University.

Jong-Yeon Park, PhD

Professor @ Moffitt Cancer Center, University of South Florida. PhD from University of Alabama. MPH. Prostate cancer expert.

Seoung-Yong Park, PhD

Professor @ Konkuk University. PhD from Chiba University. Veterinary medical center. KRICT R&D Director.

Please reload

With collaboration from a global network of expert consultants

Under construction.

©  ViroCure 2018

#119, 3802 Spectrum Blvd. Tampa, FL 33612

Tel: 813-615-9367

Fax: 813-615-9334